The blockbuster drug era is not only alive—it’s accelerating. In FY2025, the world’s largest pharmaceutical companies reported revenues ranging from $41 billion to over $65 billion, powered by a concentrated set of high-performing therapies. These top-selling medicines are not just commercial successes; they are reshaping treatment paradigms across oncology, immunology, and metabolic diseases.
A closer look at the top three drugs from each pharma giant reveals clear trends in where the industry is heading—and which therapeutic areas continue to dominate global healthcare spending.
The Rise of the $60B+ Pharma Club
One of the most striking developments in 2025 is the expansion of the $60B+ revenue club. Four companies—Eli Lilly, Pfizer, AbbVie, and Johnson & Johnson—have crossed this milestone, signaling both scale and strong product portfolios.
Eli Lilly leads the pack at $65.2 billion, largely fueled by its diabetes and obesity franchise. Pfizer and AbbVie follow closely, each benefiting from diversified portfolios spanning vaccines, immunology, and specialty therapeutics. Johnson & Johnson continues to leverage its strong presence in immunology and oncology.
This clustering at the top suggests that scale is increasingly tied to a handful of blockbuster drugs capable of generating multi-billion-dollar annual revenues.
GLP-1 Agonists: The Market Game-Changer
If there is one therapeutic class that defined 2025, it is GLP-1 receptor agonists. Originally developed for diabetes, these drugs have exploded in demand due to their effectiveness in weight management.
Novo Nordisk’s Ozempic, Wegovy, and Rybelsus continue to dominate the metabolic space, while Eli Lilly’s Mounjaro and Zepbound are rapidly gaining ground. These therapies are not just revenue drivers—they are transforming how obesity is treated globally, shifting it from a lifestyle issue to a medically managed condition.
The competitive landscape is heating up. Companies like Pfizer and AbbVie are actively investing in this space, signaling that the GLP-1 boom is far from peaking. The real question is how pricing, supply constraints, and next-generation formulations will shape the market in 2026 and beyond.
Oncology Remains the Industry Backbone
Despite the buzz around metabolic drugs, oncology continues to be the financial backbone of the pharmaceutical industry.
Merck’s Keytruda remains one of the most successful drugs in history, anchoring the company’s $58.1 billion revenue. Its broad range of indications across cancers ensures continued dominance. Similarly, AstraZeneca’s Tagrisso and Imfinzi highlight the company’s strength in targeted therapies and immuno-oncology.
Bristol Myers Squibb also maintains a strong oncology presence with Opdivo, complemented by Eliquis in cardiovascular care. Roche, long a leader in oncology, continues to benefit from drugs like Ocrevus and Hemlibra, although its portfolio is increasingly diversified.
The continued success of oncology drugs underscores the high unmet need in cancer treatment—and the willingness of healthcare systems to invest heavily in innovative therapies.
Immunology’s Resilience in a Post-Humira World
Immunology remains another cornerstone of pharma revenues, particularly for AbbVie. Following the loss of exclusivity for Humira, many questioned how the company would sustain its dominance. The answer lies in Skyrizi and Rinvoq, which have successfully offset biosimilar erosion and reestablished AbbVie’s leadership in the space.
Johnson & Johnson’s Stelara and Tremfya, along with Novartis’ Cosentyx, further demonstrate the strength of immunology portfolios across the industry. These drugs address chronic conditions like psoriasis, Crohn’s disease, and arthritis—areas with long-term treatment cycles and stable demand.
This resilience highlights a key industry strategy: lifecycle management and next-generation therapies can effectively cushion the impact of patent expirations.
Vaccines and Specialty Therapies Hold Their Ground
While not as headline-grabbing as GLP-1s or oncology drugs, vaccines and specialty therapies continue to contribute significantly to revenues.
Merck’s Gardasil 9 remains a global leader in HPV prevention, while Pfizer’s Prevnar 20 strengthens its vaccine portfolio. GSK’s Shingrix continues to perform strongly in the shingles vaccine market.
These products provide steady, recurring revenue streams and play a crucial role in balancing more volatile therapeutic areas.
Final Thoughts
The 2025 pharma landscape is defined by a mix of innovation and consolidation. A small number of blockbuster drugs are driving a disproportionate share of revenues, while therapeutic focus areas—GLP-1, oncology, and immunology—continue to dominate.
What stands out most is the industry’s ability to evolve. Whether it’s replacing aging blockbusters, capitalizing on new scientific breakthroughs, or expanding into adjacent therapeutic areas, pharma giants are proving that the blockbuster model is far from obsolete.
As competition intensifies and new entrants emerge, 2026 will be a critical year to watch—especially in the rapidly evolving obesity and metabolic treatment space.